National Addictions Vigilance Intervention and Prevention Program™, NAVIPPRO™, offers scientifically-developed comprehensive risk management for prescription opioids, stimulants, and other schedule II or III therapeutic agents. Developed in part with support from National Institute on Drug Abuse (NIDA), the NAVIPPRO system provides pharmaceutical companies with national, real-time, product-specific data for: postmarketing surveillance, signal detection and verification, intervention and prevention programs.
Loading...

ADVANCING      PUBLIC HEALTH

 

NAVIPPRO strives to minimize non-medical use of prescription opioids and stimulants through surveillance, signal detection, and through our online prevention and intervention programs.

 

IMPROVING THE RISK-BENEFIT BALANCE OF PRESCRIPTION MEDICATIONS

Developed in part with support from the National Institute on Drug Abuse (NIDA), NAVIPPRO is a turnkey solution that integrates the four key components of an effective REMS: national, real-time, product-specific surveillance; signal detection; signal verification; and empirically-validated prevention and intervention programs.

Loading...

KEY FEATURES:

  • Monitors prescription medication abuse, including opioids and stimulants
  • Consists of three major proprietary databases and draws from other national public databases
  • Applies sophisticated signal detection techniques such as statistical process control (SPC)
  • Provides expert analysis of incoming data to create customized, up-to-date reports
  • Incorporates proven intervention, prevention, and educational programs
  • Capable of including data on new stimulant and schedule II and III therapeutic agents as they enter the market

 

SURVEILLANCE PREVENTION AND INTERVENTION SIGNAL VERIFICATION SIGNAL DETECTION